DOI:

10.37988/1811-153X_2022_3_67

Mathematical prediction of probability and development of recurrence of medication-related osteonecrosis of the jaw

Downloads

Authors

  • N.G. Vinogradova 1, 2, PhD in Medical Sciences, top-class doctor at the Maxillofacial Surgery Department; assistant professor of the Surgical dentistry, otorhinolaryngology and maxillofacial surgery Department
    ORCID: 0000-0002-1065-7650
  • J.V. Sakulina 3, PhD in Pedagogy, associate professor of the Information law Department
    ORCID: 0000-0001-9966-0997
  • M.P. Kharitonova 2, PhD in Medical Sciences, PhD in Medical Sciences, full professor of the Prosthodontics and general dentistry Department
    ORCID: 0000-0003-0243-7989
  • K.V. Lvov 1, top-class doctor and head of the Maxillofacial surgery Division
    ORCID: 0000-0003-1591-8116
  • 1 Central municipal clinical hospital no. 23, 620017, Yekaterinburg, Russia
  • 2 Ural State Medical University, 620014, Yekaterinburg, Russia
  • 3 Ural State Law University, 620137, Yekaterinburg, Russia

Abstract

Medication-related osteonecrosis of the jaw is an atypical osteomyelitis of the jaw that develops while taking medications. Despite numerous publications, there are no clear criteria in the literature for the probability of the occurrence and recurrence of MRONJ, depending on various factors. Purpose - to develop a mathematical model with the ability to predict the probability of occurrence and development of recurrence of drug-associated osteonecrosis of the jaw based on statistical analysis. . 61 patients with a diagnosis of medication-related osteonecrosis of the jaw were included in the statistical analysis by a blind selective method; all patients received therapy with bone-modifying agents for bone metastases from malignant neoplasms of various localizations. As statistical features, we used the patient’s gender, age, the period of taking the bone-modifying agent, the duration of the disease, the stage of the disease at the time of treatment, bone density according to Mich. The study consisted of several stages, a statistical analysis was carried out using the following methods - descriptive statistics, regression statistics, analysis of variance, correlation analysis, research on individual characteristics. . Based on the results of all stages of statistical analysis, no gender dependence was identified. By the method of descriptive statistics, the average age of the patient was determined, which was 64.9±1.7 years. It was found that the probability of developing medication-related osteonecrosis of the jaw increases with increasing time of taking bone-modifying agents. Analysis of variance and correlation revealed a direct positive relationship between bone type and the probability of the disease. . Age, duration of taking bone-modifying agents, type of bone tissue are predictive criteria for the development of medication-related osteonecrosis of the jaw. The probability of relapse increases in patients receiving targeted therapy with tyrosine kinase blockers and monoclonal antibodies that block vascular endothelial growth factors.

Key words:

medication-related, osteonecrosis, jaw, osteomyelitis, bone-modifying agents

For Citation

[1]
Vinogradova N.G., Sakulina J.V., Kharitonova M.P., Lvov K.V. Mathematical prediction of probability and development of recurrence of medication-related osteonecrosis of the jaw. Clinical Dentistry (Russia).  2022; 25 (3): 67—75. DOI: 10.37988/1811-153X_2022_3_67

References

  1. Albanese M., Zotti F., Capocasale G., Bonetti S., Lonardi F., Nocini P.F. Conservative non-surgical management in medication related osteonecrosis of the jaw: A retrospective study. Clin Exp Dent Res. 2020; 6 (5): 512—518. PMID: 32614524
  2. Bujaldón-Rodríguez R., Gómez-Moreno G., Leizaola-Cardesa I.O., Aguilar-Salvatierra A. Resolution of a case of denosumab-related osteonecrosis of the jaw after tooth extraction. Eur Rev Med Pharmacol Sci. 2019; 23 (6): 2314—2317. PMID: 30964153
  3. Everts-Graber J., Lehmann D., Burkard J.P., Schaller B., Gahl B., Häuselmann H., Studer U., Ziswiler H.R., Reichenbach S., Lehmann T. Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Miner Res. 2022; 37 (2): 340—348. PMID: 34787342
  4. Lee S.H., Choi S.Y., Bae M.S., Kwon T.G. Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment. Maxillofac Plast Reconstr Surg. 2021; 43 (1): 24. PMID: 34236538
  5. Yarom N., Shapiro C.L., Peterson D.E., Van Poznak C.H., Bohlke K., Ruggiero S.L., Migliorati C.A., Khan A., Morrison A., Anderson H., Murphy B.A., Alston-Johnson D., Mendes R.A., Beadle B.M., Jensen S.B., Saunders D.P. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol. 2019; 37 (25): 2270—2290. PMID: 31329513
  6. Bagrova S.G., Kopp M.V., Kutukova S.I., Manzyuk L.V., Semiglazova T.Y. The use of osteomodifying agents (OMA) for the prevention and treatment of bone pathology with malignant neoplasms. Malignant tumors. 2020; 10 (3s2—2): 35—44 (In Russ.). DOI: 10.18027/2224-5057-2020-10-3s2-38
  7. Srivichit B., Thonusin C., Chattipakorn N., Chattipakorn S.C. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw. Arch Toxicol. 2022; 96 (5): 1227—1255. PMID: 35199244
  8. Akita Y., Kuroshima S., Nakajima K., Hayano H., Kanai R., Sasaki M., Sawase T. Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice. J Bone Miner Metab. 2018; 36 (5): 547—559. PMID: 29043461
  9. Giudice A., Antonelli A., Chiarella E., Baudi F., Barni T., Di Vito A. The case of medication-related osteonecrosis of the jaw addressed from a pathogenic point of view. Innovative therapeutic strategies: Focus on the most recent discoveries on oral mesenchymal stem cell-derived exosomes. Pharmaceuticals (Basel). 2020; 13 (12): E423. PMID: 33255626
  10. Li J.W., Wang J.Y., Yu R.Q., Huo L., Zheng L.W. Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid. BMC Res Notes. 2022; 15 (1): 12. PMID: 35012647
  11. Açil Y., Möller B., Niehoff P., Rachko K., Gassling V., Wiltfang J., Simon M.J. The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg. 2012; 40 (8): e229—35. PMID: 22082730
  12. Basso F.G., Pansani T.N., de Oliveira C.F., Turrioni A.P., Soares D.G., Hebling J., Costa C.A. Cytotoxic effects of zoledronic acid on human epithelial cells and gingival fibroblasts. Braz Dent J. 2013; 24 (6): 551—8. PMID: 24474348
  13. Katsarelis H., Shah N.P., Dhariwal D.K., Pazianas M. Infection and medication-related osteonecrosis of the jaw. J Dent Res. 2015; 94 (4): 534—9. PMID: 25710950
  14. Ivanyushko T.P., Polyakov K.A., Medvedev Y.A., Shamanaev S.V., Trofimov D.Y., Abramov D.D., Balyikin R.A. Conditionally pathogenic microorganisms in patients with bisphosphonate jaw osteonecrosis. Stomatology. 2016; 1: 44—48 (In Russ.). eLIBRARY ID: 25675495
  15. Anabtawi M., Tweedale H., Mahmood H. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2021; 50 (4): 501—510. PMID: 32800674
  16. Bedogni A., Bettini G., Bedogni G., Basso D., Gatti D., Valisena S., Brunello A., Sorio M., Berno T., Giannini S., Navaglia F., Plebani M., Nocini P.F., Blandamura S., Saia G., Bertoldo F. Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study. J Craniomaxillofac Surg. 2019; 47 (8): 1203—1208. PMID: 30929994
  17. Botelho J., Machado V., Proença L., Delgado A.S., Mendes J.J. Vitamin D deficiency and oral health: A comprehensive review. Nutrients. 2020; 12 (5): E1471. PMID: 32438644
  18. Dalle Carbonare L., Mottes M., Valenti M.T. Medication-related osteonecrosis of the jaw (MRONJ): Are antiresorptive drugs the main culprits or only accomplices? The triggering role of vitamin D deficiency. Nutrients. 2021; 13 (2): 561. PMID: 33567797
  19. Heim N., Warwas F.B., Wilms C.T., Reich R.H., Martini M. Vitamin D (25-OHD) deficiency may increase the prevalence of medication-related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2017; 45 (12): 2068—2074. PMID: 29102331
  20. He L., Sun X., Liu Z., Qiu Y., Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci. 2020; 12 (1): 30. PMID: 33087699
  21. Fung P., Bedogni G., Bedogni A., Petrie A., Porter S., Campisi G., Bagan J., Fusco V., Saia G., Acham S., Musto P., Petrucci M.T., Diz P., Colella G., Mignogna M.D., Pentenero M., Arduino P., Lodi G., Maiorana C., Manfredi M., Hallberg P., Wadelius M., Takaoka K., Leung Y.Y., Bonacina R., Schiødt M., Lakatos P., Taylor T., De Riu G., Favini G., Rogers S.N., Pirmohamed M., Nicoletti P., GENVABO Consortium., Fedele S. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. Oral Dis. 2017; 23 (4): 477—483. PMID: 28039941
  22. Kozutsumi R., Kuroshima S., Kaneko H., Sasaki M., Ishisaki A., Sawase T. Zoledronic acid deteriorates soft and hard tissue healing of murine tooth extraction sockets in a dose-dependent manner. Calcif Tissue Int. 2022; 110 (1): 104—116. PMID: 34363509
  23. Otto S., Tröltzsch M., Jambrovic V., Panya S., Probst F., Ristow O., Ehrenfeld M., Pautke C. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg. 2015; 43 (6): 847—54. PMID: 25958767
  24. Soutome S., Hayashida S., Funahara M., Sakamoto Y., Kojima Y., Yanamoto S., Umeda M. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? PLoS One. 2018; 13 (7): e0201343. PMID: 30048523
  25. Mingazeva A.Z., Averyanov S.V., Tselishcheva A.A. Risk factors for the occurrence of bisphosphonate-associated jaw osteonecrosis in patients with osteoporosis. Dental Forum. 2020; 4 (79): 44—45 (In Russ.). eLIBRARY ID: 44082045
  26. Romero-Ruiz M.M., Romero-Serrano M., Serrano-González A., Serrera-Figallo M.Á., Gutiérrez-Pérez J.L., Torres-Lagares D. Proposal for a preventive protocol for medication-related osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2021; 26 (3): e314-e326. PMID: 33037798
  27. Vinogradova N., L’vov K., Haritonova M., Zhirnov A. Application of autologous plasma in the treatment of medication related osteonecrosis of the jaw. Actual Problems in Dentistry. 2019; 4: 103—108 (In Russ.). eLIBRARY ID: 42364564
  28. Vinogradova N.G., Haritonova M.P., Lvov K.V. Laser doppler flowmetry as the method of sequestrectomy determination lines with bisphosphonate osteonecrosis of the jaw. Ural Medical Journal. 2019; 2 (170): 101—105 (In Russ.). eLIBRARY ID: 37185703
  29. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B., O.’Ryan F., American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014; 72 (10): 1938—56. PMID: 25234529
  30. Vinogradov A., Vinogradov K. The choice of method for statistical analysis of medical data and method of graphical representation of results. Social Aspects of Population Health. 2019; 4: 9 (In Russ.). eLIBRARY ID: 39379110
  31. Vinogradova NatalyaG., Solomatina LiliyaV., Kharitonova MarinaP., L’vov KonstantinV., Borzunov DmitryYu. Optical bone density as a prognostic risk factor for the development of medication-related osteonecrosis of the jaw in patients with bone metastases. Orthopaedic Genius. 2020; 4: 539—543 (In Russ.). eLIBRARY ID: 44386375
  32. Crew K.D., Shane E., Cremers S., McMahon D.J., Irani D., Hershman D.L. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol. 2009; 27 (13): 2151—6. PMID: 19349547

Downloads

Received

May 19, 2022

Accepted

August 6, 2022

Published on

October 30, 2022